Mr. Stapley has deep experience in the genomic diagnostics industry, including significant expertise building and leading complex global operations.

Her career spans over 40 years in regulated diagnostics and life science markets. She cofounded Veracyte in 2008 and served as Chief Executive Officer and Chairman of the Board until June 1, 2021, when she assumed the role of Executive Chairwoman.

Dr. Kennedy’s scientific leadership, Veracyte continually pushes the boundaries of what is possible in genomic diagnostics, using big data and machine learning to develop tests that answer critical clinical questions.

Rebecca Chambers has extensive healthcare leadership experience, previously serving as Chief Financial Officer for Outset Medical, a publicly traded medical technology company focused on reducing dialysis cost and complexity.

Rob Brainin is a seasoned professional with over 20 years of executive life sciences and healthcare experience, and a proven track record of using emerging technologies and data science to improve healthcare.

Bill Zondler’s career spans more than 25 years in information technology, including over 20 years in clinical laboratories and the pharmaceutical, medical device, life sciences and biotechnology industries.

Morten Frost joined Veracyte in January 2021 as General Manager, Pulmonology & Breast Cancer, with global responsibility for strategic business planning and tactical execution, for the company’s lung cancer and interstitial lung disease (ILD) products.

Tina S. Nova, Ph.D., serves as Veracyte’s general manager, Thyroid & Urology, leading the company’s flagship Afirma franchise in thyroid cancer and market-leading Decipher business in urologic cancers.

Vincent Fert has extensive diagnostic leadership experience, most recently serving as the Founder, Chairman and Chief Executive Officer of HalioDx, an immuno-oncology diagnostics company recently acquired by Veracyte.

Stephane Debono is an entrepreneur who brings more than 25 years of executive experience in life sciences and health care to Veracyte. He most recently served as Deputy Chief Executive Officer of HalioDx, an immuno-oncology diagnostics company, and Chief Executive Officer of its U.S. subsidiary, HalioDx, Inc., and also led HalioDx’s Executive Committee to manage the company’s growth.

Corinne Danan serves as Veracyte’s General Manager, Biopharma, leading the company’s offerings to biopharmaceutical companies. Ms. Danan brings more than 30 years of executive experience in the pharmaceutical, life sciences and healthcare industries, as well as strong leadership in Commercial Operations, to her role at Veracyte.

Fabienne Hermitte, Ph.D., brings deep expertise in clinical diagnostics to her role at Veracyte. She cofounded HalioDx, an immuno-oncology diagnostics company, in 2015. At HalioDx, she led the Regulatory, Quality, Medical Affairs, Clinical Development and Diagnostic Marketing teams prior to the company’s acquisition by Veracyte in August 2021

In this role, she works in tandem with the Chief Executive Officer and executive team to communicate the company’s strategic vision and value proposition to investors and other audiences and ensures that the market-leading company’s brand is articulated in product and other communications.